Ben Goertzel advocates for decentralized AGI development, pushes back on government ownership of AI
Ben Goertzel, the founder and CEO of SingularityNET, isn’t buying the idea that governments should own AI companies. On June 2, Goertzel published a pointed critique responding to US Senator Bernie Sanders’ op-ed advocating for government ownership of major AI firms, arguing instead that the path to Artificial General Intelligence should be collaborative, open-source, and decentralized.
The core of Goertzel’s argument is straightforward: handing control of AI to any single entity, whether a corporation or a government, risks concentrating power in ways that stifle progress.
The case against nationalization
Goertzel has been beating this drum since at least the early 2010s, long before decentralized AI became a trendy talking point. His position is that beneficial AGI outcomes are far more achievable when no single organization holds the keys to the technology.
SingularityNET and the ASI Alliance
Goertzel isn’t just philosophizing. He’s been building infrastructure to back up the thesis. SingularityNET, which he founded in 2017, operates as a decentralized marketplace for AI algorithms and services. The idea is that any developer can contribute AI tools and any user can access them, without a central authority deciding who gets to participate.
In 2024, the project took a significant step by forming the Artificial Superintelligence (ASI) Alliance. This brought together SingularityNET with Fetch.ai, Ocean Protocol, and CUDOS through a community token merger. The alliance is designed around open-source principles and governance structures specifically built to prevent any single entity from dominating the ecosystem.
As of June 2026, SingularityNET has completed the integration of the FET (ASI) token across its platform. The token now facilitates both transactions and governance for new AI services launched on the network.
What this means for investors
Despite the significance of Goertzel’s statements, immediate market reactions were minimal. No major price swings followed the post, which suggests that the crypto market views this more as an ongoing ideological conversation than a catalyst event.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
